Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
12.03. | Immunovia AB: Immunovia announces updated financial calendar | 178 | PR Newswire | LUND, Sweden, March 12, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq) (IMMNOV: Stockholm), the diagnostics company with the mission to increase pancreatic cancer survival rates through... ► Artikel lesen | |
21.02. | Immunovia reports Q4 results | 1 | Seeking Alpha | ||
21.02. | Immunovia AB: Immunovia Publishes Full Year Report for 2023 | 213 | PR Newswire | LUND, Sweden, Feb. 21, 2024 /PRNewswire/ --
October-December 2023
Net sales, which for the quarter only included royal- ties, amounted to kSEK 155 (502).Net earnings were MSEK... ► Artikel lesen | |
14.02. | Immunovia AB: Invitation to Immunovia's Q4 presentation | 234 | PR Newswire | LUND, Sweden, Feb. 14, 2024 /PRNewswire/ -- Immunovia will publish its full year 2023 results on February 21, 2024 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference... ► Artikel lesen | |
31.01. | Immunovia hires new VP for clinical studies | 1 | Investing.com | ||
31.01. | Immunovia AB: Immunovia appoints Norma Alonzo Palma as new Vice President of Clinical and Medical Affairs | 256 | PR Newswire | LUND, Sweden, Jan. 31, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the diagnostics company with the mission to increase pancreatic cancer survival rates through early detection... ► Artikel lesen | |
04.01. | Immunovia AB: Immunovia announces financial calendar for financial year 2024 | 288 | PR Newswire | LUND, Sweden, Jan. 4, 2024 /PRNewswire/ -- Immunovia, a diagnostic company with the vision to revolutionize blood-based diagnostics and survival rates for patients with cancer, announces... ► Artikel lesen | |
21.11.23 | Bulletin from the extraordinary general meeting in Immunovia AB | 349 | PR Newswire | LUND, Sweden, Nov. 21, 2023 /PRNewswire/ -- On 21st
November 2023, an extraordinary general meeting ("EGM") was held in Immunovia AB (publ), 556730-4299, at Medicon Village in Lund.... ► Artikel lesen | |
09.11.23 | Immunovia reports Q3 results | 5 | Seeking Alpha | ||
09.11.23 | Immunovia AB: Immunovia Publishes Interim Report for January-September 2023 | 215 | PR Newswire | LUND, Sweden, Nov. 9, 2023 /PRNewswire/ --
July-September 2023
Net sales amounted to KSEK 488 (358) divided by sales of tests KSEK 70 (111) and royalties KSEK 418 (247).Net earnings... ► Artikel lesen | |
07.11.23 | Immunovia AB: Immunovia successfully completes discovery phase of next-generation test development | 380 | PR Newswire | LUND, Sweden, Nov. 7, 2023 /PRNewswire/ -- Immunovia (Nasdaq Stockholm: IMMNOV), the diagnostics company focused on early detection of pancreatic cancer, today announced the successful completion... ► Artikel lesen | |
02.11.23 | Immunovia AB: Invitation to Immunovia's Q3 presentation | 248 | PR Newswire | LUND, Sweden, Nov. 2, 2023 /PRNewswire/ -- Immunovia will publish its third quarter 2023 results on November 9, 2023 at 8:30 am CET. Analysts, investors and media are invited to a webcast... ► Artikel lesen | |
27.10.23 | CONVENING NOTICE - EXTRAORDINARY GENERAL MEETING IN IMMUNOVIA AB (PUBL) | 335 | PR Newswire | LUND, SWEDEN, Oct. 27, 2023 /PRNewswire/ -- Immunovia AB (publ), reg. no. 556730-4299 (the "Company"), hereby gives notice that an extraordinary general meeting will take place on Tuesday... ► Artikel lesen | |
03.10.23 | Nomination Committee appointed for Immunovia AB (Publ) | 264 | PR Newswire | LUND, Sweden, Oct. 3, 2023 /PRNewswire/ -- According to the instructions for the Nomination Committee of Immunovia AB (Publ) that were adopted at the Annual General Meeting on May 26, 2023... ► Artikel lesen | |
30.08.23 | Immunovia AB: Immunovia Publishes Interim Report for January-June 2023 | 363 | PR Newswire | LUND, Sweden, Aug. 30, 2023 /PRNewswire/ --
April-June 2023
Net sales amounted to kSEK 412 (103) divided by sales of tests kSEK 351 (45) and royalties kSEK 61 (58).Net... ► Artikel lesen | |
23.08.23 | Immunovia AB: Invitation to Immunovia's Q2 presentation | 445 | PR Newswire | LUND, Sweden, Aug. 23, 2023 /PRNewswire/ -- Immunovia will publish its second quarter 2023 results on August 30, 2023 at 8:30 am CET. Analysts, investors and media are invited to a webcast... ► Artikel lesen | |
19.07.23 | Immunovia AB: Immunovia announces updated financial calendar | 434 | PR Newswire | LUND, Sweden, July 19, 2023 /PRNewswire/ -- Immunovia (Nasdaq Stockholm: IMMNOV), the diagnostics company focused on early detection of pancreatic cancer, updates its financial calendar for... ► Artikel lesen | |
12.07.23 | Immunovia AB: Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection | 553 | PR Newswire | LUND, Sweden, July 12, 2023 /PRNewswire/ -- Immunovia (Nasdaq Stockholm: IMMNOV), the diagnostics company focused on early detection of pancreatic cancer, today announced plans to restructure... ► Artikel lesen | |
09.06.23 | Immunovia AB: Chief Executive Officer, Jeff Borcherding, buys Immunovia shares | 409 | PR Newswire | LUND, Sweden, June 9, 2023 /PRNewswire/ -- Immunovia AB (Nasdaq: IMMNOV) announces today that Jeff Borcherding, CEO of Immunovia, has purchased 350 000 shares for approximately 670 KSEK.His... ► Artikel lesen | |
31.05.23 | Change in number of shares and votes in Immunovia AB (publ) | 402 | PR Newswire | LUND, Sweden, May 31, 2023 /PRNewswire/ -- The number of shares and votes in Immunovia AB (publ) ("Immunovia") have changed as a result of new shares being issued in the rights issue resolved... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
TELADOC HEALTH | 14,190 | +0,64 % | Here's Why Investors Should Hold Teladoc (TDOC) Stock Now | ||
ROKU | 60,50 | -0,13 % | Best Stock to Buy Right Now: Roku vs Netflix | ||
BECTON DICKINSON | 229,50 | +0,88 % | BD boosts U.S. production as FDA warns against using plastic syringes from China | ||
DEXCOM | 129,08 | +0,17 % | DexCom Aktie: Insiderverkäufe und Marktbewertung | DexCom, ein Unternehmen im Bereich der medizinischen Geräte, spezialisiert auf kontinuierliche Glukoseüberwachungssysteme für Diabetiker, zeigt eine signifikante Aktivität auf Führungsebene. Ein leitender... ► Artikel lesen | |
HIMS & HERS HEALTH | 14,750 | +1,72 % | Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS), the leading health and wellness platform, today announced financial results for the fourth... ► Artikel lesen | |
INVITAE | 0,110 | 0,00 % | Invitae Corporation: Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, today announced estimated unaudited fourth quarter and full year 2023 revenue, gross profit... ► Artikel lesen | |
ATOSSA THERAPEUTICS | 1,700 | +1,43 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient | SEATTLE, March 19, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), today announced that the pre-menopausal, Estrogen Receptor positive (ER+) / Human... ► Artikel lesen | |
EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 | -- Third Consecutive Year of Phexxi Net Sales Growth --
-- Total Operating Expense Reduced 64% from 2022 Levels --
-- Sales and marketing expense as a percentage of net sales was 54% for the fourth... ► Artikel lesen | |
RYMAN HEALTHCARE | 2,460 | +0,41 % | RYMAN HEALTHCARE LIMITED: New governance appointments at Ryman Healthcare | ||
INVIVO THERAPEUTICS HOLDINGS | 0,175 | 0,00 % | NSE - INVIVO THERAPEUTICS HOLDINGS CORP. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
CYTOSORBENTS | 0,829 | -3,04 % | CytoSorbents Reports Fourth Quarter and Full Year 2023 Results | STAR-T trial results selected for a Breakout Presentation at the American Association of Thoracic Surgery Annual Meeting in late-April 2024 CytoSorbents intends to submit DrugSorb-ATR for regulatory... ► Artikel lesen | |
ONTRAK | 0,750 | +40,19 % | Ontrak Launches New Engagement System | ||
TEMPEST THERAPEUTICS | 3,660 | +5,78 % | Tempest Therapeutics: Tempest Reports Year End 2023 Financial Results and Provides Business Update | Announced positive randomized first-line HCC data showing superiority of TPST-1120 combination therapy across multiple study endpoints compared to standard of careReported new biomarker data in two... ► Artikel lesen | |
WELLBEING DIGITAL SCIENCES | 0,007 | -100,00 % | Predictmedix AI Inc.: Predictmedix AI and KGK Science Partner to Enhance Health Research and Product Development | Canadian partnership opens up a new vertical for Predictmedix with significant potentialIntegration with clinical trials likely to improve efficiency translating into cost savings and ROI for Clinical... ► Artikel lesen | |
SENSEONICS | 0,525 | +0,96 % | Senseonics Holdings, Inc. - 8-K, Current Report |